is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
CPhI & P-MEC India and Global Business Reports are pleased to bring you the Gujarat Pharma 2020 report, sharing our view on the most attractive opportunities in the Indian pharma market. The report provides an outlook for the Gujarat region in India as a pharma hub, based on the knowledge of industry experts who have been interviewed.
We speak to Deepak Sapra, CEO of Active Pharmaceutical Ingredients and Services at Dr. Reddy's Laboratories, for his perspective on the current state of the Indian healthcare and pharmaceuticals sector.
The CPhI & P-MEC India team has been working hard to actively monitor the COVID-19 situation and as it stands, we do not plan to postpone or cancel our event, which will take place on the original dates of 25-27 November 2020. The wellbeing of our community remains our top priority and as an Organized Gathering we will be implementing the World Health Organization’s recommended measures for gatherings, as well as following the steps advised by local health authorities.
The Booming Indian Pharmaceutical Market, a future powerhouse for R&D and manufacturers of pharmaceuticals with a market value of US$32bn by 2024 and 70-80% of branded generics in the retail market.
2019 edition saw a rise in overall attendees, with harmonization and innovation driving increased industry dynamism.
What does 2019 have in store for Pharma? We asked industry Thought Leaders to name one disruptive trend or technology that will have a significant impact on the market in the year ahead.
Savita V Jayaram looks at the reasons for slow growth in India’s agrichemical manufacturing industry, the impediments to change and the barriers to reducing dependency on Chinese imports.
CPhI & P-MEC India opens as report ranks India the world’s fastest improving pharma market and first for ‘growth potential’ for 2019.
By Vicky Qing Xia & Ronald A. Rader.
Posted on www.pharmoutsourcing.com
Recent growth in the biopharmaceutical industry in both China, and India suggest a future positive outlook for contract manufacturing in both regions.
The 2017 CPhI Indian Pharma insight report is designed to evaluate the overall growth prospects of domestic Indian Pharma companies and foreign pharmaceutical companies working within the India pharmaceutical market.
The new venue will see the exhibition now hosted in a single venue, bringing it closer to the Indian regulatory and legislative capital. New Delhi is also the country’s main international transport hub and will encourage an increased international attendance. In total, more than 50,000 people from 122 countries are expected, along with nearly 1500 exhibitors.
Biopharmaceutical drugs are normally manufactured at large facilities dedicated to a single product, using processes that are difficult to reconfigure. To help make more of these drugs available, MIT researchers have developed a new way to rapidly manufacture biopharmaceuticals on demand.